ATE208820T1 - Humanisierte antikoerper - Google Patents

Humanisierte antikoerper

Info

Publication number
ATE208820T1
ATE208820T1 AT94917751T AT94917751T ATE208820T1 AT E208820 T1 ATE208820 T1 AT E208820T1 AT 94917751 T AT94917751 T AT 94917751T AT 94917751 T AT94917751 T AT 94917751T AT E208820 T1 ATE208820 T1 AT E208820T1
Authority
AT
Austria
Prior art keywords
humanized antibodies
antibodies
specificity
preparing
processes
Prior art date
Application number
AT94917751T
Other languages
English (en)
Inventor
Susan Adrienne Morgan
John Spencer Emtage
Mark William Bodmer
Diljeet Singh Athwal
Original Assignee
Celltech Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB939312415A external-priority patent/GB9312415D0/en
Priority claimed from GB9401597A external-priority patent/GB9401597D0/en
Priority claimed from GB9402499A external-priority patent/GB9402499D0/en
Priority claimed from GB9406222A external-priority patent/GB9406222D0/en
Application filed by Celltech Therapeutics Ltd filed Critical Celltech Therapeutics Ltd
Application granted granted Critical
Publication of ATE208820T1 publication Critical patent/ATE208820T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT94917751T 1993-06-16 1994-06-15 Humanisierte antikoerper ATE208820T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB939312415A GB9312415D0 (en) 1993-06-16 1993-06-16 Altered antibodies
GB9401597A GB9401597D0 (en) 1994-01-27 1994-01-27 Altered antibodies
GB9402499A GB9402499D0 (en) 1994-02-09 1994-02-09 Altered abtibodies
GB9406222A GB9406222D0 (en) 1994-03-29 1994-03-29 Huminised antibodies
PCT/GB1994/001291 WO1994029451A2 (en) 1993-06-16 1994-06-15 Humanised antibodies

Publications (1)

Publication Number Publication Date
ATE208820T1 true ATE208820T1 (de) 2001-11-15

Family

ID=27451033

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94917751T ATE208820T1 (de) 1993-06-16 1994-06-15 Humanisierte antikoerper

Country Status (8)

Country Link
US (1) US6180377B1 (de)
EP (1) EP0715653B1 (de)
JP (1) JP3653093B2 (de)
AT (1) ATE208820T1 (de)
AU (1) AU694926B2 (de)
CA (1) CA2163344A1 (de)
DE (1) DE69429095T2 (de)
WO (1) WO1994029451A2 (de)

Families Citing this family (245)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
JPH10511652A (ja) * 1994-12-23 1998-11-10 ラボラトワール・オン・ソシエテ・アノニム 炎症性疾患の予防および／または治療に対するｍｈｃ−ｉｉ結合および／またはｍｈｃ−ｉｉ模倣分子の使用
EP0835306A1 (de) * 1995-06-30 1998-04-15 Kobenhavns Universitet Durch filamentöse phagen-bibliothek hergestellte rekombinante antikörper, die gegen ein mhc-peptid komplex gerichtet sind
US7247302B1 (en) * 1996-08-02 2007-07-24 Bristol-Myers Squibb Company Method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis
US6528624B1 (en) * 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
DE69942607D1 (de) * 1998-04-14 2010-09-02 Chugai Pharmaceutical Co Ltd Neues cytokinartiges protein
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
US6673843B2 (en) * 1999-06-30 2004-01-06 Emory University Curcumin and curcuminoid inhibition of angiogenesis
US20040019187A1 (en) * 2000-05-12 2004-01-29 Zoltan Nagy Immunomodulatory human mhc class II antigens-binding polypeptides
EP1156062A1 (de) * 2000-05-12 2001-11-21 GPC Biotech AG Immunmodulierende an humane MHC Klasse II Antigen bindende Peptide/Proteine
US7521047B2 (en) 2000-05-12 2009-04-21 Gpc Biotech Ag Human polypeptides causing or leading to the killing of cells including lymphoid tumor cells
US6656700B2 (en) * 2000-05-26 2003-12-02 Amersham Plc Isoforms of human pregnancy-associated protein-E
US6686188B2 (en) * 2000-05-26 2004-02-03 Amersham Plc Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
US8568766B2 (en) * 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
US20020123474A1 (en) * 2000-10-04 2002-09-05 Shannon Mark E. Human GTP-Rho binding protein2
US7051028B2 (en) * 2000-11-15 2006-05-23 Ndsu-Research Foundation Concurrency control in high performance database systems
US20030049800A1 (en) * 2000-12-15 2003-03-13 Saravis Calvin A. Compositions and methods for producing antibodies to low molecular weight analytes
JP2004525109A (ja) 2001-02-15 2004-08-19 キング・ファーマシューティカルズ・インコーポレイティッド 安定化された甲状腺ホルモン医薬組成物、及びその製法
CN1531554A (zh) * 2001-06-26 2004-09-22 ��������ҽѧ���޹�˾ 血纤维蛋白d-二聚体片段特异性的、来源于dd-3b6/22的人源化抗体
US20040078837A1 (en) * 2001-08-02 2004-04-22 Shannon Mark E. Four human zinc-finger-containing proteins: MDZ3, MDZ4, MDZ7 and MDZ12
US7101569B2 (en) 2001-08-14 2006-09-05 Franz G Andrew Methods of administering levothyroxine pharmaceutical compositions
AU2002327704A1 (en) * 2001-09-21 2003-04-01 Raven Biotechnologies, Inc. Antibodies that bind to cancer-associated antigen cytokeratin 8 and methods of use thereof
US20030082188A1 (en) * 2001-10-11 2003-05-01 Tso J. Yun Treatment of prostate cancer by inhibitors of NCAM2
EP1441766B1 (de) * 2001-10-16 2011-09-14 MacroGenics West, Inc. An das krebsassoziierte antigen cd46 bindende antikörper und verwendungsverfahren dafür
KR100988949B1 (ko) * 2001-10-25 2010-10-20 제넨테크, 인크. 당단백질 조성물
US7811992B2 (en) 2002-02-06 2010-10-12 Stasys Technologies, Inc. Anti-infarction molecules
EP1534729A2 (de) * 2002-02-26 2005-06-01 University of Utah Research Foundation Mit bluthochdruck und virusknospung assoziierte nedd4l-varianten
US8435529B2 (en) 2002-06-14 2013-05-07 Immunomedics, Inc. Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
US9745380B2 (en) * 2002-03-01 2017-08-29 Immunomedics, Inc. RS7 antibodies
CA2478047C (en) 2002-03-01 2014-01-21 Immunomedics, Inc. Rs7 antibodies
US9770517B2 (en) 2002-03-01 2017-09-26 Immunomedics, Inc. Anti-Trop-2 antibody-drug conjugates and uses thereof
US20090011991A1 (en) * 2002-03-08 2009-01-08 Emory University Novel Curcuminoid-Factor VIIA Constructs as Suppressors of Tumor Growth and Angiogenesis
EP1572078A4 (de) * 2002-03-08 2006-08-09 Univ Emory NEUE CURCUMINOID-FAKTOR-VIIa-KONSTRUKTE ALS MITTEL ZUR UNTERDRÜCKUNG VON TUMORWACHSTUM UND ANGIOGENESE
EP1492870A4 (de) * 2002-04-12 2005-08-03 Raven Biotechnologies Inc An integrin-alpha-v-beta-6 bindende antikörper sowie verfahren zur verwendung davon
SG187991A1 (en) * 2002-05-02 2013-03-28 Wyeth Corp Calicheamicin derivative-carrier conjugates
GB0210121D0 (en) * 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
US20040048319A1 (en) * 2002-05-03 2004-03-11 Mather Jennie P. ALCAM and ALCAM modulators
CA2485120C (en) 2002-05-06 2013-02-19 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Identification of novel broadly cross-reactive hiv-1 neutralizing human monoclonal antibodies
ATE488530T1 (de) * 2002-06-19 2010-12-15 Raven Biotechnologies Inc Internalisierende antikörper spezifisch für das raag10 zelloberflächenziel
EP2116604A1 (de) 2002-08-05 2009-11-11 University of Rochester Proteinumwandlungsdomäne / Deaminasechimäre Proteine, zugehörige Verbindungen und Verwendungen davon
FR2844513B1 (fr) * 2002-09-13 2007-08-03 Lab Francais Du Fractionnement Anticorps pour adcc et induisant la production de cytokines.
FR2844455B1 (fr) * 2002-09-13 2007-12-14 Lab Francais Du Fractionnement Traitement des pathologies echappant a la reponse immune par des anticorps optimises
CA2500901A1 (en) * 2002-10-04 2004-04-22 Rinat Neuroscience Corp. Methods for treating cardiac arrhythmia and preventing death due to cardiac arrhythmia using ngf antagonists
EP1556083B1 (de) * 2002-10-08 2011-02-02 Rinat Neuroscience Corp. Verfahren zur behandlung von postoperativen schmerzen durch verabreichung eines antikörpers gegen nervenwachstumsfaktor und diesen enthaltende zusammensetzungen
US7255860B2 (en) * 2002-10-08 2007-08-14 Rinat Neuroscience Corp. Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody
UA80447C2 (en) 2002-10-08 2007-09-25 Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
EP1633786A4 (de) * 2002-10-09 2007-07-25 Rinat Neuroscience Corp Verfahren zur behandlung der alzheimer-krankheit mit antikörpern gegen amyloid-beta-peptid und zusammensetzungen daraus
US7405061B2 (en) * 2002-11-13 2008-07-29 Raven Biotechnologies, Inc. Antigen PIPA and antibodies that bind thereto
JP4824312B2 (ja) * 2002-11-26 2011-11-30 ユニバーシティ オブ ユタ リサーチ ファンデーション 微小孔物質、被分析物の局在化及び定量の方法、並びに被分析物の局在化及び定量用物品
US7597936B2 (en) * 2002-11-26 2009-10-06 University Of Utah Research Foundation Method of producing a pigmented composite microporous material
JP2006513187A (ja) * 2002-12-23 2006-04-20 ライナット ニューロサイエンス コーポレイション タキソール誘発性感覚性ニューロパシーを処置するための方法
EP2270048B1 (de) 2002-12-24 2015-11-11 Rinat Neuroscience Corp. Anti-NGF Antikörper und Verfahren zu ihrer Verwendung
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
US9498530B2 (en) 2002-12-24 2016-11-22 Rinat Neuroscience Corp. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
KR20050111598A (ko) 2003-02-19 2005-11-25 리나트 뉴로사이언스 코퍼레이션 신경 성장 인자 길항제 및 ｎｓａｉｄ를 투여함으로써통증을 치료하는 방법 및 그것을 함유하는 조성물
CA2517416A1 (en) * 2003-02-28 2004-09-10 Howard Florey Institute Of Experimental Physiology And Medicine Therapeutic compositions
US20070014786A1 (en) * 2003-03-20 2007-01-18 Rinat Neuroscience Corp. Methods for treating taxol-induced gut disorder
AU2003901325A0 (en) * 2003-03-21 2003-04-03 Stephen Locarnini Therapeutic, prophylactic and diagnostic agents
US20050232926A1 (en) * 2003-06-06 2005-10-20 Oncomax Acquisition Corp. Antibodies specific for cancer associated antigen SM5-1 and uses thereof
CA2528182A1 (en) * 2003-06-06 2005-06-16 Oncomax Acquisition Corp. Antibodies specific for cancer associated antigen sm5-1 and uses thereof
CN1279056C (zh) * 2003-06-06 2006-10-11 马菁 肿瘤相关抗原sm5－1的特异性抗体及其应用
DE602004029252D1 (de) 2003-06-13 2010-11-04 Biogen Idec Inc Aglycosyl-anti-cd154 (cd40-ligand) antikörper und deren verwendungen
JP2007502837A (ja) * 2003-08-18 2007-02-15 テシス バイオサイエンス， インコーポレイテッド 小型エピトープ抗体を使用するサンプルの複雑さを低減するための方法
NZ545968A (en) * 2003-09-18 2010-01-29 Raven Biotechnologies Inc KID3 and KID3 antibodies that bind thereto
ES2343965T3 (es) 2003-11-25 2010-08-13 The Government Of The United States, As Represented By The Secretary Of Health And Human Services Anticuerpos anti-cd22 e inmunocongujados mutados.
WO2005058251A2 (en) * 2003-12-15 2005-06-30 Dendreon Corporation Hla-dr-specific antibodies, compositions and methods
EP1711517A4 (de) 2004-01-21 2008-02-13 Univ Utah Res Found MUTANTER NATRIUMKANAL NAv1.7 UND DAMIT VERBUNDENE VERFAHREN
DK1718967T3 (da) 2004-02-03 2013-06-03 Diadexus Inc Metoder til at detektere Lp-PLA2 aktivitet
US8435539B2 (en) * 2004-02-13 2013-05-07 Immunomedics, Inc. Delivery system for cytotoxic drugs by bispecific antibody pretargeting
US8491914B2 (en) * 2004-02-13 2013-07-23 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for delivery of interference RNA
US9550838B2 (en) 2004-02-13 2017-01-24 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
US8551480B2 (en) 2004-02-13 2013-10-08 Immunomedics, Inc. Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity
US8883160B2 (en) * 2004-02-13 2014-11-11 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
US9481878B2 (en) 2004-02-13 2016-11-01 Immunomedics, Inc. Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity
US20110064754A1 (en) * 2005-03-03 2011-03-17 Center For Molecular Medicine And Immunology Immunoconjugates Comprising Poxvirus-Derived Peptides and Antibodies Against Antigen-Presenting Cells for Subunit-Based Poxvirus Vaccines
US8652484B2 (en) 2004-02-13 2014-02-18 Immunomedics, Inc. Delivery system for cytotoxic drugs by bispecific antibody pretargeting
US20110020273A1 (en) * 2005-04-06 2011-01-27 Ibc Pharmaceuticals, Inc. Bispecific Immunocytokine Dock-and-Lock (DNL) Complexes and Therapeutic Use Thereof
AU2005243247B2 (en) * 2004-04-07 2012-03-01 Regents Of The University Of Minnesota Methods for treating bone cancer pain by administering a nerve growth factor antagonist
AU2005252699B2 (en) 2004-06-07 2010-12-23 Macrogenics West, Inc. Transferrin receptor antibodies
CZ200755A3 (cs) 2004-07-26 2007-04-11 Biogen Idec Ma Inc. Peptidy protilátek anti-CD154
GEP20115195B (en) * 2004-07-30 2011-04-11 Rinat Neuroscience Corp Antibodies directed against amyloid-beta peptide and use thereof
ES2641815T3 (es) 2004-10-29 2017-11-14 Eisai R&D Management Co., Ltd. Tratamiento para enfermedades inflamatorias
WO2006060871A1 (en) 2004-12-10 2006-06-15 The Corporation Of The Trustees Of The Order Of The Sisters Of Mercy In Queensland Binding partners of antibodies specific for dendritic cell antigens
WO2006076584A2 (en) 2005-01-12 2006-07-20 Raven Biotechnologies, Inc. Kid31 and antibodies that bind thereto
WO2006083852A2 (en) * 2005-01-31 2006-08-10 Raven Biotechnologies, Inc. Luca2 and antibodies that bind thereto
CA2596273C (en) 2005-02-02 2017-11-14 Raven Biotechnologies, Inc. Adam-9 modulators
WO2006084078A2 (en) * 2005-02-02 2006-08-10 Raven Biotechnologies, Inc. Jam-3 and antibodies that bind thereto
WO2006084092A2 (en) * 2005-02-03 2006-08-10 Raven Biotechnologies, Inc. Antibodies to oncostatin m receptor
KR101363252B1 (ko) * 2005-02-04 2014-02-13 레이븐 바이오테크놀로지스, 인코퍼레이티드 Ｅｐｈａ2에 결합하는 항체 및 그것의 사용방법
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
US10058621B2 (en) 2015-06-25 2018-08-28 Immunomedics, Inc. Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers
ES2829566T3 (es) * 2005-03-03 2021-06-01 Immunomedics Inc Anticuerpos L243 humanizados
AU2011253938B2 (en) * 2005-03-03 2014-02-06 Immunomedics, Inc. Humanized L243 antibodies
WO2006104989A2 (en) * 2005-03-29 2006-10-05 Verenium Corporation Altered antibody fc regions and uses thereof
AR054260A1 (es) * 2005-04-26 2007-06-13 Rinat Neuroscience Corp Metodos de tratamiento de enfermedades de la neurona motora inferior y composiciones utilizadas en los mismos
PE20061323A1 (es) 2005-04-29 2007-02-09 Rinat Neuroscience Corp Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos
EP2371843B1 (de) 2005-05-19 2014-09-17 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services Funktionelle Epitope des Pneumokokken-Antigens und deren Nutzung
ES2569917T3 (es) 2005-06-21 2016-05-13 Xoma (Us) Llc Anticuerpos y fragmentos de los mismos que se unen a IL-1beta
WO2007014169A2 (en) 2005-07-22 2007-02-01 Y's Therapeutics Co, Ltd. Anti-cd26 antibodies and methods of use thereof
US7794951B2 (en) * 2005-10-18 2010-09-14 University Of Massachusetts Medical School SREBP2gc transcription factors and uses thereof
ES2433251T5 (es) 2005-11-14 2020-03-13 Teva Pharmaceuticals Int Gmbh Anticuerpos antagonistas dirigidos contra un péptido relacionado con el gen de la calcitonina y procedimientos que utilizan los mismos
AU2007223427A1 (en) * 2006-03-01 2007-09-13 University Of Utah Research Foundation Methods and compositions related to cyclic peptide synthesis
US8470965B2 (en) * 2006-03-01 2013-06-25 University Of Utah Research Foundation Methods and compositions related to cyclic peptide synthesis
EP1996942A1 (de) * 2006-03-10 2008-12-03 Tethys Bioscience, Inc. Multiplex-protein-fraktionierung
EP2104516B1 (de) 2006-11-01 2015-01-07 University of Rochester Verfahren und zusammensetzungen in zusammenhang mit der struktur und funktion von apobec3g
AU2007325872B2 (en) 2006-11-08 2012-12-13 Macrogenics West, Inc. TES7 and antibodies that bind thereto
US7492312B2 (en) * 2006-11-14 2009-02-17 Fam Adly T Multiplicative mismatched filters for optimum range sidelobe suppression in barker code reception
EP3124045A3 (de) 2006-12-20 2017-05-03 Xoma (Us) Llc Behandlung von il-1-beta-bedingten erkrankungen
JP2010514839A (ja) * 2007-01-03 2010-05-06 バーナム インスティテュート フォー メディカル リサーチ クロット結合化合物に関連する方法および組成物
SG196697A1 (en) 2007-03-22 2014-02-13 Biogen Idec Inc Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154 and uses thereof
MX2009012676A (es) 2007-05-23 2010-02-12 Uab Research Foundation Neuraminidasa neumococica no toxica y sus usos.
WO2009026496A1 (en) * 2007-08-22 2009-02-26 University Of Southern California Grp78 and tumor angiogenesis
EP2195331B1 (de) * 2007-08-28 2013-11-20 Uab Research Foundation Synthetische, apolipoprotein e nachahmende polypeptide und anwendungsverfahren
US8557767B2 (en) 2007-08-28 2013-10-15 Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use
EP2201040A1 (de) * 2007-09-24 2010-06-30 Vanderbilt University Monoklonale antikörper gegen das respiratorische synzytialvirus und ihre verwendung
HUE027358T2 (en) * 2007-11-26 2016-09-28 Bayer Ip Gmbh Anti-mesothelin antibodies and their applications
CA2706317C (en) * 2007-12-03 2017-06-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Doc1 compositions and methods for treating cancer
DK2391650T3 (en) 2007-12-20 2015-01-12 Xoma Us Llc Methods of treating gout
JP5785490B2 (ja) 2008-04-02 2015-09-30 マクロジェニクス，インコーポレーテッド Ｂｃｒ複合体特異的抗体およびその使用方法
EP3062106B1 (de) 2008-04-16 2020-11-11 The Johns Hopkins University Verfahren zur bestimmung von varianten des andorgen rezeptors in prostatakrebs
WO2009150623A1 (en) 2008-06-13 2009-12-17 Pfizer Inc Treatment of chronic prostatitis
AU2008360658B2 (en) 2008-08-15 2015-02-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services S0X9, prostaglandin D2 and retinoic acid for treating pigmentary conditions and melanoma
TWI516501B (zh) 2008-09-12 2016-01-11 禮納特神經系統科學公司 Ｐｃｓｋ９拮抗劑類
CA2736864C (en) 2008-09-19 2020-10-13 Pfizer Inc. Stable liquid antibody formulation
US20120070443A1 (en) 2008-12-02 2012-03-22 University Of Utah Research Foundation Pde1 as a target therapeutic in heart disease
WO2010086828A2 (en) 2009-02-02 2010-08-05 Rinat Neuroscience Corporation Agonist anti-trkb monoclonal antibodies
UY32560A (es) 2009-04-29 2010-11-30 Bayer Schering Pharma Ag Inmunoconjugados de antimesotelina y usos de los mismos
WO2010146511A1 (en) 2009-06-17 2010-12-23 Pfizer Limited Treatment of overactive bladder
US9090690B2 (en) 2009-06-18 2015-07-28 Pfizer Inc. Anti Notch-1 antibodies
AU2010282340B2 (en) 2009-08-13 2016-12-22 The Johns Hopkins University Methods of modulating immune function
CA2773665C (en) 2009-09-11 2018-02-20 Ira H. Pastan Improved pseudomonas exotoxin a with reduced immunogenicity
US20110081293A1 (en) 2009-10-07 2011-04-07 Sanford-Burnham Medical Research Institute Methods and compositions related to clot-binding lipid compounds
JO3437B1 (ar) 2009-10-30 2019-10-20 Esai R & D Man Co Ltd أجسام مضادة محسنة مضادة للفراكتالكين البشري واستخداماتها
WO2011068801A2 (en) 2009-12-01 2011-06-09 The Rockefeller University Methods for identifying compounds that modulate ion channel activity of a kir channel
WO2011075725A1 (en) 2009-12-18 2011-06-23 Sanford-Burnham Medical Research Institute Methods and compositions related to clot-binding compounds
WO2011085354A1 (en) * 2010-01-11 2011-07-14 Center For Molecular Medicine And Immunology Enhanced cytotoxicity of anti-cd74 and anti-hla-dr antibodies with interferon-gamma
US20110207789A1 (en) 2010-02-19 2011-08-25 Ye Fang Methods related to casein kinase ii (ck2) inhibitors and the use of purinosome-disrupting ck2 inhibitors for anti-cancer therapy agents
AR080291A1 (es) 2010-02-24 2012-03-28 Rinat Neuroscience Corp Anticuerpos antagonistas anti receptor de il-7 y procedimientos
PH12012501751A1 (en) 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
PH12018501083A1 (en) 2010-03-04 2019-02-18 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
BR112012022917A2 (pt) 2010-03-11 2017-01-10 Pfizer anticorpos com ligação a antígeno dependente de ph
EP2407173A1 (de) * 2010-07-13 2012-01-18 Netris Pharma Verfahren und Zusammensetzungen zur Induzierung der Apoptose von tumorzellenexpressierender Shh
EP2569335B1 (de) 2010-05-14 2018-08-22 Orega Biotech Verfahren zur behandlung und/oder prävention von zellproliferationsstörungen mit il-17-antagonisten
GB201012420D0 (en) 2010-07-23 2010-09-08 Univ Erasmus Medical Ct Foetal heamoglobin inhibitor
GB201012410D0 (en) 2010-07-23 2010-09-08 Medical Res Council Intracellular immunity
EP2598126A2 (de) 2010-07-30 2013-06-05 Saint Louis University Verfahren zur behandlung von schmerz
EP2603526A1 (de) 2010-08-13 2013-06-19 Medimmune Limited Monomere polypeptide mit abweichenden fc-regionen und verwendungsverfahren
WO2012022734A2 (en) 2010-08-16 2012-02-23 Medimmune Limited Anti-icam-1 antibodies and methods of use
JP2013535694A (ja) 2010-08-19 2013-09-12 ハワード フローリー インスティチュート 神経病理学的疾患の検出および調節におけるｔａｍ受容体およびｔａｍ受容体リガンド
WO2012024650A2 (en) 2010-08-19 2012-02-23 Abbott Laboratories Anti-ngf antibodies and their use
RU2622083C2 (ru) 2010-12-15 2017-06-09 ВАЙЕТ ЭлЭлСи Антитела против notch1
US9051619B2 (en) 2011-03-25 2015-06-09 Florida Agricultural and Mechanical University (FAMU) Methods and compositions for prostate cancer metastasis
ES2692268T5 (en) 2011-03-29 2025-02-26 Roche Glycart Ag Antibody fc variants
MX2013012905A (es) 2011-05-06 2014-04-25 Us Gov Health & Human Serv Inmunotoxina recombinante dirigida a la mesotelina.
US9587021B2 (en) 2011-05-21 2017-03-07 Macrogenics, Inc. CD3-binding molecules capable of binding to human and non-human CD3
HRP20180858T1 (hr) 2011-07-11 2018-09-21 Glenmark Pharmaceuticals S.A. Protutijela koja se vežu na ox40 i njihove uporabe
ES2749349T3 (es) 2011-11-07 2020-03-19 Medimmune Llc Proteínas de unión multiespecíficas y multivalentes y usos de las mismas
US8871908B2 (en) 2011-11-11 2014-10-28 Rinat Neuroscience Corp. Antibodies specific for Trop-2 and their uses
JP6320300B2 (ja) 2011-12-19 2018-05-09 ゾーマ （ユーエス） リミテッド ライアビリティ カンパニー 座瘡を治療するための方法
PT2794905T (pt) 2011-12-20 2020-06-30 Medimmune Llc Polipéptidos modificados para estrutura de anticorpos bispecíficos
GB201202268D0 (en) 2012-02-09 2012-03-28 Medical Res Council Intracellular immunity
WO2013158485A1 (en) 2012-04-18 2013-10-24 Massachusetts Institute Of Technology Menainv and cancer invasion and metastasis
JP6629069B2 (ja) 2012-06-06 2020-01-15 ゾエティス・エルエルシー イヌ化抗ｎｇｆ抗体およびその方法
LT3495387T (lt) 2012-07-13 2021-11-25 Roche Glycart Ag Bispecifiniai anti-vegf / anti-ang-2 antikūnai ir jų panaudojimas akių kraujagyslių ligoms gydyti
US9382329B2 (en) 2012-08-14 2016-07-05 Ibc Pharmaceuticals, Inc. Disease therapy by inducing immune response to Trop-2 expressing cells
WO2014099671A1 (en) * 2012-12-20 2014-06-26 Bluebird Bio, Inc. Chimeric antigen receptors and immune cells targeting b cell malignancies
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
EP2968370A4 (de) 2013-03-14 2016-09-21 Univ Maryland Mittel zur androgenrezeptor-abwärtsregelung und verwendungen davon
KR101809072B1 (ko) 2013-08-02 2017-12-14 화이자 인코포레이티드 항-cxcr4 항체 및 항체-약물 접합체
EP3033088A4 (de) 2013-08-12 2017-03-08 Tokai Pharmaceuticals, Inc. Biomarker zur behandlung neoplastischer störungen mit androgen-anzielenden therapien
WO2015050959A1 (en) 2013-10-01 2015-04-09 Yale University Anti-kit antibodies and methods of use thereof
PT3052192T (pt) 2013-10-02 2020-09-24 Medimmune Llc Anticorpos neutralizantes anti-influenza a e suas utilizações
WO2015087187A1 (en) 2013-12-10 2015-06-18 Rinat Neuroscience Corp. Anti-sclerostin antibodies
TWI754319B (zh) 2014-03-19 2022-02-01 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
MX378344B (es) 2014-03-21 2025-03-10 Teva Pharmaceuticals Int Gmbh Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos.
US10774387B2 (en) 2014-05-19 2020-09-15 The Johns Hopkins University Methods for identifying androgen receptor splice variants in subjects having castration resistant prostate cancer
SG10201913680PA (en) 2014-05-29 2020-03-30 Macrogenics Inc Tri-specific binding molecules that specifically bind to multiple cancer antigens and methods of use thereof
CA2954780A1 (en) 2014-07-15 2016-01-21 Medimmune, Llc Neutralizing anti-influenza b antibodies and uses thereof
CA2954475C (en) 2014-07-31 2023-05-16 Uab Research Foundation Apoe mimetic peptides and higher potency to clear plasma cholesterol
EP3186393A4 (de) 2014-08-25 2018-01-10 The Johns Hopkins University Verfahren und zusammensetzungen im zusammenhang mit prostatakrebstherapeutika
KR20170065662A (ko) 2014-10-18 2017-06-13 화이자 인코포레이티드 항-il-7r 항체 조성물
ES2809455T3 (es) 2014-11-17 2021-03-04 Regeneron Pharma Métodos para tratamiento tumoral usando anticuerpo biespecífico CD3xCD20
EP3237000A1 (de) 2014-12-23 2017-11-01 Pfizer Inc Stabile wässrige antikörperformulierung für anti-tnf-alpha-antikörper
HK1247215A1 (zh) 2015-01-26 2018-09-21 Macrogenics, Inc. 包含dr5-结合结构域的多价分子
WO2016161010A2 (en) 2015-03-30 2016-10-06 Regeneron Pharmaceuticals, Inc. Heavy chain constant regions with reduced binding to fc gamma receptors
IL310723A (en) 2015-04-13 2024-04-01 Pfizer Therapeutic antibodies and their uses
US9797907B2 (en) 2015-04-22 2017-10-24 Immunomedics, Inc. Isolation, detection, diagnosis and/or characterization of circulating Trop-2-positive cancer cells
TWI773646B (zh) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
US10877045B2 (en) 2015-07-21 2020-12-29 Saint Louis University Compositions and methods for diagnosing and treating endometriosis-related infertility
AU2016298227B9 (en) 2015-07-30 2019-10-31 Macrogenics, Inc. PD-1-binding molecules and methods of use thereof
KR102777500B1 (ko) 2015-09-23 2025-03-11 리제너론 파아마슈티컬스, 인크. 최적화된 항-cd3 이중특이적 항체 및 이의 용도
CN108136010A (zh) 2015-10-08 2018-06-08 宏观基因有限公司 用于治疗癌症的联合疗法
JP6955507B2 (ja) 2015-12-14 2021-10-27 マクロジェニクス，インコーポレーテッド Ｐｄ‐１及びｃｔｌａ‐４との免疫応答性を有する二重特異性並びにその使用方法
US11007251B2 (en) 2015-12-17 2021-05-18 The Johns Hopkins University Ameliorating systemic sclerosis with death receptor agonists
CN109219618B (zh) 2016-01-21 2022-08-09 辉瑞大药厂 针对表皮生长因子受体变体iii和cd3的单特异性和双特异性抗体及其用途
TW201730212A (zh) 2016-02-17 2017-09-01 宏觀基因股份有限公司 Ｒｏｒ１－結合分子及其使用方法
US10443054B2 (en) 2016-03-06 2019-10-15 Massachusetts Institute Of Technology Methods for identifying and treating invasive/metastatic breast cancers
AU2017248264B2 (en) 2016-04-07 2020-01-30 The Johns Hopkins University Compositions and methods for treating pancreatitis and pain with death receptor agonists
CA3020864A1 (en) 2016-04-15 2017-10-19 Macrogenics, Inc. Novel b7-h3-binding molecules, antibody drug conjugates thereof and methods of use thereof
AR108377A1 (es) 2016-05-06 2018-08-15 Medimmune Llc Proteínas de unión biespecíficas y sus usos
CA3026490A1 (en) 2016-06-09 2017-12-14 University Of Leicester Monoclonal antibodies, compositions and methods for detecting mucin-like protein (mlp) as a biomarker for ovarian and pancreatic cancer
AU2017306709A1 (en) 2016-08-05 2019-03-14 Humabs, BioMed SA Anti-o2 antibodies and uses thereof
KR102650803B1 (ko) 2016-10-05 2024-03-25 유니버시티 오브 센트럴 플로리다 리서치 파운데이션, 인코포레이티드 Nk 세포 및 항-pdl1 암 요법과 관련된 방법 및 조성물
KR102613430B1 (ko) 2016-10-19 2023-12-18 더 스크립스 리서치 인스티튜트 인간화된 표적화 모이어티 및/또는 최적화된 키메라 항원 수용체-상호작용 도메인을 갖는 키메라 항원 수용체 효과기 세포 스위치 및 이의 용도
SG11201903063UA (en) 2016-10-19 2019-05-30 Medimmune Llc Anti-o1 antibodies and uses thereof
AU2017382234B2 (en) 2016-12-23 2025-01-30 Macrogenics, Inc. ADAM9-binding molecules, and methods of use thereof
SI3558391T1 (sl) 2016-12-23 2022-06-30 Immunogen, Inc. Imunokonjugati, ciljno usmerjeni na ADAM9, in načini njihove uporabe
JP7132232B2 (ja) 2017-02-24 2022-09-06 マクロジェニクス，インコーポレーテッド Ｃｄ１３７及び腫瘍抗原に結合できる二重特異性結合分子並びにその使用
PE20242042A1 (es) 2017-06-02 2024-10-10 Pfizer Anticuerpos especificos para flt3 y sus usos
US12025615B2 (en) 2017-09-15 2024-07-02 Arizona Board Of Regents On Behalf Of Arizona State University Methods of classifying response to immunotherapy for cancer
JP2021505637A (ja) 2017-12-12 2021-02-18 マクロジェニクス，インコーポレーテッド 二重特異性ｃｄ１６結合分子、及び疾患の治療におけるその使用
WO2019118686A1 (en) 2017-12-13 2019-06-20 North Carolina State University Compositions comprising chemotherapeutic agents and checkpoint inhibitors and methods of use
TWI878213B (zh) 2018-02-01 2025-04-01 美商輝瑞大藥廠 對cd70具特異性抗體及其用途
TW201936633A (zh) 2018-02-01 2019-09-16 美商輝瑞大藥廠 標靶至cd70的嵌合抗原受體
WO2019154776A1 (en) 2018-02-06 2019-08-15 F. Hoffmann-La Roche Ag Treatment of ophthalmologic diseases
SG11202007572VA (en) 2018-02-15 2020-09-29 Macrogenics Inc Variant cd3-binding domains and their use in combination therapies for the treatment of disease
MX2020009526A (es) 2018-03-12 2020-10-28 Zoetis Services Llc Anticuerpos anti-ngf y metodos de estos.
BR112020022595A2 (pt) 2018-05-23 2021-02-09 Pfizer Inc. anticorpos específicos para gucy2c e usos dos mesmos
DK3797121T3 (da) 2018-05-23 2024-07-08 Pfizer Antistoffer, der er specifikke for CD3, og anvendelser deraf
AU2019282264A1 (en) 2018-06-05 2020-11-26 Amgen Inc. Modulating antibody dependent cellular phagocytosis
MX2020013466A (es) 2018-06-26 2021-04-19 Immunogen Inc Inmunoconjugados dirigidos a adam9 y métodos para usarlos.
JP7579570B2 (ja) 2018-06-29 2024-11-08 ノース・キャロライナ・ステイト・ユニヴァーシティ 術後治療用ｉｎ ｓｉｔｕ噴霧生体応答性免疫療法ゲル
CN112566936B (zh) 2018-08-21 2024-07-12 阿尔伯特爱因斯坦医学院 针对人tim-3的单克隆抗体
PT3844189T (pt) 2018-08-31 2025-01-29 Regeneron Pharma Estratégia de dosagem que mitiga a síndrome de libertação de citocinas para anticorpos bisepecíficos contra cd3/c20
AU2019339895A1 (en) 2018-09-11 2021-03-11 Amgen Inc. Methods of modulating antibody-dependent cell-mediated cytotoxicity
EP4588483A3 (de) 2018-10-03 2025-09-24 University of Pittsburgh- Of the Commonwealth System of Higher Education Kovalente adaptersynnotch- und chimäre antigenrezeptoren (cars) für programmierbares antigen-targeting
SG11202103064YA (en) 2018-10-29 2021-05-28 Hoffmann La Roche Antibody formulation
WO2020102779A1 (en) 2018-11-16 2020-05-22 Albert Einstein College Of Medicine MONOCLONAL ANTIBODIES AGAINST IgV DOMAIN OF B7-H3 AND USES THEREOF
US20220074951A1 (en) 2018-12-27 2022-03-10 University Of Utah Research Foundation Compositions and methods useful in detecting and treating multiple sclerosis and other demyelinating diseases
IL285437B2 (en) 2019-02-07 2026-05-01 Hudson Inst Of Medical Research Method for treating or preventing cancer by targeting the extracellular portion of keratin 14 on cancer cells
EP3941524A1 (de) 2019-03-19 2022-01-26 Albert Einstein College of Medicine Monoklonale antikörper zur vorbeugung und behandlung von herpes-simplex-virusinfektionen
WO2020236901A1 (en) 2019-05-20 2020-11-26 University Of Pittsburgh-Of The Commonwealth System Of Higher Education A novel therapy for erythropoietic protoporphyria (epp) and x-linked protoporphyria (xlp)
WO2020257640A1 (en) 2019-06-21 2020-12-24 Vaccinex, Inc. Combination therapy with semaphorin-4d blockade (sema4d) and dc1 therapy
EP4038222A4 (de) 2019-10-02 2023-10-18 Arizona Board of Regents on behalf of Arizona State University Verfahren und zusammensetzungen zur identifizierung von neoantigenen zur verwendung bei der behandlung und vorbeugung von krebs
JP7745556B2 (ja) 2020-02-21 2025-09-29 マクロジェニクス，インコーポレーテッド Ｃｄ１３７結合分子及びその使用
WO2021224687A1 (en) 2020-05-08 2021-11-11 Novocure Gmbh Compositions and methods of applying alternating electric fields to pluripotent stem cells
BR112023002843A2 (pt) 2020-08-18 2023-03-14 Omeros Corp Anticorpo isolado ou fragmento de ligação a antígeno do mesmo, molécula de ácido nucleico, vetor de clonagem ou cassete de expressão, célula, métodos para gerar um anticorpo isolado ou fragmento de ligação a antígeno do mesmo, para determinar a presença ou quantidade de fator d maduro e de pró-fator d em uma amostra de teste, para avaliar o grau de ativação do caminho alternativo de complemento (apc) em uma amostra de teste, para monitorar a eficácia de tratamento com um anticorpo inibidor de lectina serina protease 3 de ligação a manana ou fragmento de ligação a antígeno do mesmo e para tratar um sujeito mamífero sofrendo de ou em risco de desenvolver uma doença ou distúrbio do caminho alternativo, composição, substrato para o uso em um imunoensaio, kit para detectar a presença ou quantidade de fator d maduro em uma amostra de teste, composição farmacêutica, e, artigo de fabricação
US12043671B2 (en) 2021-06-16 2024-07-23 Gundersen Lutheran Medical Foundation, Inc. Antibodies targeting an amphiregulin-derived cell surface neo-epitope
WO2023139292A1 (en) 2022-01-24 2023-07-27 Cambridge Enterprise Limited Tau therapy
WO2024107752A2 (en) 2022-11-15 2024-05-23 Onestone Therapeutics Llc Compositions and methods for immunomodulatory bifunctional fusion molecules
KR20260026033A (ko) 2023-06-14 2026-02-25 이뮤트린 리미티드 항-원섬유 항체
WO2025184211A1 (en) 2024-02-27 2025-09-04 Bristol-Myers Squibb Company Anti-ceacam5 antibody drug conjugates
US20250361320A1 (en) 2024-02-27 2025-11-27 Bristol-Myers Squibb Company Anti-ceacam5 antibodies and uses thereof
US20260115307A1 (en) 2024-10-31 2026-04-30 Bristol-Myers Squibb Company Anti-fucosyl-gm1 antibody drug conjugates

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3269354D1 (en) * 1981-06-25 1986-04-03 Univ Leland Stanford Junior Allele specific immunotherapeutic method and dosage form
GB8607679D0 (en) * 1986-03-27 1986-04-30 Winter G P Recombinant dna product
EP0307434B2 (de) * 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Geänderte antikörper
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
GB9015908D0 (en) * 1990-07-19 1990-09-05 Celltech Ltd Multivalent immunoglobulin
GB9109645D0 (en) * 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies

Also Published As

Publication number Publication date
EP0715653A1 (de) 1996-06-12
DE69429095D1 (de) 2001-12-20
DE69429095T2 (de) 2002-09-12
AU694926B2 (en) 1998-08-06
WO1994029451A2 (en) 1994-12-22
CA2163344A1 (en) 1994-12-22
WO1994029451A3 (en) 1995-02-16
AU6934294A (en) 1995-01-03
JPH08511421A (ja) 1996-12-03
US6180377B1 (en) 2001-01-30
EP0715653B1 (de) 2001-11-14
JP3653093B2 (ja) 2005-05-25

Similar Documents

Publication Publication Date Title
DE69429095D1 (de) Humanisierte antikoerper
NO2006008I1 (no) Natalizumab, anti alfa-4 integrin humanized monoclonal antibody
FI981799L (fi) DNA-molekyylejä, jotka koodaavat CD25 sitovia molekyylejä
ATE218387T1 (de) Antikörperreinigung
PT941121E (pt) Preparados farmaceuticos liofilizados, estaveis, de anticorpos monoclonais ou policlonais
PL330075A1 (en) Antibodies against the ed-b domain of fibronectin, their construction and application
CA2056102A1 (en) Method for the production of antibodies
ES2106195T3 (es) Anticuerpo igg aglicosilado anti cd3.
WO2003078468A3 (de) Verwendung einer an cd28 bindenden wirksubstanz zur herstellung einer pharmazeutischen zusammensetzung
DK0538754T3 (da) Anvendelse af antistofholdige præparater til immunundertrykkelse
GR3025630T3 (en) Monoclonal antibody against human IgE
ITRM920457A0 (it) Anticorpi monoclonali che riconoscono un epitopo della p-glicoproteinaumana.
EP1491632A3 (de) Anti-alphavbeta3 humanizierte monoklonale Antikörper
DK1144006T3 (da) Synergistisk inhibering af HIV-1-fusion og -binding, præparater og antistoffer dertil
DE3581288D1 (de) Antileishmania monoklonale antikoerper, diese antikoerper ausscheidende hybridomas, von diesen antikoerpern erkannte leishmaniaantigene, verfahren zur herstellung und verwendung von diesen monoklonalen antikoerpern und antigenen.
MX9301858A (es) Anticuerpos monoclonales neutralizantes de hiv-humano recombinante para prevencion y tratamiento de infeccion hiv.
DK407987A (da) Apolipoprotein b-specifikke monoklonale antistoffer og hybridomer, som producerer disse antistoffer
FR2560212B1 (fr) Anticorps monoclonaux contre l'interferon a2 et hybridomes produisant de tels anticorps
DK0585570T3 (da) Granulocytbindende antistofkonstrukter, deres fremstilling og anvendelse
NO972522L (no) Monoklonale antistoffer med immunoundertrykkende aktivitet
ATE208403T1 (de) Antiidiotypische antikörper die eine immunantwort gegen den rezeptor für epidermalen wachstumsfaktor induzieren
KR930019820A (ko) 모노클로날 항-강글리오사이드 항체, 이의 제조방법 및 종양 치료제로서의 용도
BR9702101A (pt) Hibridoma e anticorpo monoclonal
DK0513565T3 (da) Monoklonale antistoffer mod plasmin-antiplasmin-komplekset, fremgangsmåde til deres fremstilling og deres anvendelse
DK0656906T3 (da) Endothelcellemolekyle, der medierer lymfocytbinding i mennesket

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties